Curis Announces Erivedge(R) Receives Positive CHMP Opinion for Conditional Approval in European Union

Recommended as Treatment for Advanced Basal Cell Carcinoma Curis Eligible for $6 Million Milestone on European Commission Approval LEXINGTON, Mass., April 26, 2013 -- (Healthcare Sales & Marketing Network) -- Curis, Inc. (CRIS), an oncology-focused c... Biopharmaceuticals, Oncology, RegulatoryCuris , Basal Cell Carcinoma, Erivedge, vismodegib
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news